JP2015529633A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015529633A5 JP2015529633A5 JP2015517672A JP2015517672A JP2015529633A5 JP 2015529633 A5 JP2015529633 A5 JP 2015529633A5 JP 2015517672 A JP2015517672 A JP 2015517672A JP 2015517672 A JP2015517672 A JP 2015517672A JP 2015529633 A5 JP2015529633 A5 JP 2015529633A5
- Authority
- JP
- Japan
- Prior art keywords
- bag3
- biological sample
- antibody
- urine
- serum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090001123 antibodies Proteins 0.000 claims 6
- 102000004965 antibodies Human genes 0.000 claims 6
- 239000012472 biological sample Substances 0.000 claims 6
- 102100019663 BAG3 Human genes 0.000 claims 5
- 101700008168 BAG3 Proteins 0.000 claims 5
- 210000002381 Plasma Anatomy 0.000 claims 4
- 210000003296 Saliva Anatomy 0.000 claims 4
- 210000002966 Serum Anatomy 0.000 claims 4
- 210000002700 Urine Anatomy 0.000 claims 4
- 238000008157 ELISA kit Methods 0.000 claims 3
- 201000010238 heart disease Diseases 0.000 claims 3
- 108010047814 Antigen-Antibody Complex Proteins 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000002757 inflammatory Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000001575 pathological Effects 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 206010002383 Angina pectoris Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 210000004204 Blood Vessels Anatomy 0.000 claims 1
- 210000000988 Bone and Bones Anatomy 0.000 claims 1
- 206010007554 Cardiac failure Diseases 0.000 claims 1
- 206010007556 Cardiac failure acute Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 210000002808 Connective Tissue Anatomy 0.000 claims 1
- 208000004981 Coronary Disease Diseases 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 206010019280 Heart failure Diseases 0.000 claims 1
- 108060003951 Immunoglobulins Proteins 0.000 claims 1
- 102000018358 Immunoglobulins Human genes 0.000 claims 1
- 206010061255 Ischaemia Diseases 0.000 claims 1
- 208000010125 Myocardial Infarction Diseases 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 102000007312 Recombinant Proteins Human genes 0.000 claims 1
- 108010033725 Recombinant Proteins Proteins 0.000 claims 1
- 210000003491 Skin Anatomy 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 230000001154 acute Effects 0.000 claims 1
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000008739 coronary artery disease Diseases 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 201000010235 heart cancer Diseases 0.000 claims 1
- 230000000642 iatrogenic Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 108010045030 monoclonal antibodies Proteins 0.000 claims 1
- 102000005614 monoclonal antibodies Human genes 0.000 claims 1
- 229960000060 monoclonal antibodies Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Claims (9)
- 生物学的試料において、抗BAG3抗体または抗BAG3抗体が可溶性BAG3に結合して形成された免疫複合体の存在を検出することによって特徴付けられた病理学的状態の診断の方法であって、
a.血清、血漿、尿、または唾液からなる生物学的試料を得るステップと、
b.生物学的試料における抗BAG3またはBAG3関連抗体の存在を決定するステップと、
を含み、
前記病理学的状態は、心臓疾患、癌、ならびに、炎症および炎症性関連疾患であって、皮膚、神経、骨、血管、および結合組織の炎症および炎症性関連疾患から選択され、および、
前記診断は、インビトロまたはエキソビボである、
ことを特徴とする方法。 - c.生物学的試料から得た値を、基準値または健康な提供者から得た値と比較するステップ、
をさらに含むことを特徴とする請求項1に記載の方法。 - 前記決定ステップbは、ELISA検査により実施されることを特徴とする請求項1に記載の方法。
- 前記血清、血漿、尿、または唾液は、哺乳類、好ましくはヒト由来であることを特徴とする請求項1から3のいずれか一項に記載の方法。
- 前記心臓疾患は、狭心症、梗塞前狭心症、心筋梗塞、心不全、急性冠疾患、虚血、急性心不全、慢性心不全、または医原性心疾患から選択されることを特徴とする請求項1に記載の方法。
- 前記癌は、膵癌、膀胱癌、および前立腺癌から選択されることを特徴とする請求項1に記載の方法。
- ELISAキットの使用であって、
前記ELISAキットは、BAG3組換えタンパク質または可溶性BAG3を捕捉するBAG3特異的マウスモノクローナル抗体AC−1、AC−2 AC−3、AC−4、AC−5、AC−rb1a、AC−rb1b、AC−rb2a、AC−rb2b、AC−rb3a、AC−rb3b、AC−rb4a、およびAC−rb4b、ならびに、ヒト免疫グロブリンを認識することができる抗体を含み、
前記キットは、生物学的試料において可溶性BAG3と結合して免疫複合体を形成する抗−BAG3抗体または抗−BAG3抗体の検出をするために用いられるものであることを特徴とするELISAキットの使用。 - 前記生物学的試料は、血清、血漿、尿、または唾液試料であることを特徴とする請求項7に記載の使用。
- 前記血清、血漿、尿、または唾液試料は、哺乳類、好ましくはヒト由来であることを特徴とする請求項8に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12172531.1 | 2012-06-19 | ||
EP12172531.1A EP2676966A1 (en) | 2012-06-19 | 2012-06-19 | BAG3 as biochemical serum and tissue marker |
PCT/EP2013/061976 WO2013189778A1 (en) | 2012-06-19 | 2013-06-11 | Bag3 as biochemical serum and tissue marker |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015529633A JP2015529633A (ja) | 2015-10-08 |
JP2015529633A5 true JP2015529633A5 (ja) | 2016-07-28 |
JP6654432B2 JP6654432B2 (ja) | 2020-02-26 |
Family
ID=48607259
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015517669A Pending JP2015521475A (ja) | 2012-06-19 | 2013-06-11 | 生化学的血清マーカーおよび組織マーカーとしてのbag3 |
JP2015517672A Expired - Fee Related JP6654432B2 (ja) | 2012-06-19 | 2013-06-11 | 生化学的血清マーカーおよび組織マーカーとしてのbag3 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015517669A Pending JP2015521475A (ja) | 2012-06-19 | 2013-06-11 | 生化学的血清マーカーおよび組織マーカーとしてのbag3 |
Country Status (12)
Country | Link |
---|---|
US (2) | US10359433B2 (ja) |
EP (3) | EP2676966A1 (ja) |
JP (2) | JP2015521475A (ja) |
KR (2) | KR20150036102A (ja) |
CN (2) | CN104619861A (ja) |
AU (2) | AU2013279604B2 (ja) |
BR (2) | BR112014031958A2 (ja) |
CA (2) | CA2876872A1 (ja) |
ES (1) | ES2795981T3 (ja) |
IN (2) | IN2014DN10562A (ja) |
PL (1) | PL2861618T3 (ja) |
WO (2) | WO2013189775A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20130403A1 (it) * | 2013-03-18 | 2014-09-19 | Biouniversa Srl | Anticorpi anti-bag3 per uso terapeutico |
CN105021825B (zh) * | 2015-07-09 | 2016-08-17 | 陈勇 | 一种检测胰腺癌相关多肽dap44的elisa试剂盒 |
CN105769900A (zh) * | 2016-03-22 | 2016-07-20 | 山西大学 | Bag3基因在制备抗膀胱癌药物中的应用 |
IT201600069391A1 (it) * | 2016-07-04 | 2016-10-04 | Univ Degli Studi Di Salerno | Uso della proteina bag3 e suoi frammenti peptidici per il controllo dell’omeostasi vascolare |
WO2021140173A1 (en) | 2020-01-10 | 2021-07-15 | Biouniversa S.R.L. | Methods and uses for treating fibrotic solid tumors with bags inhibitors |
US11940450B2 (en) | 2021-03-16 | 2024-03-26 | University Of Connecticut | Biomarker panel for non-invasive diagnosis of congenital renal dysfunction |
CN113862361B (zh) * | 2021-10-25 | 2023-08-15 | 中山大学孙逸仙纪念医院 | 一种诊断和治疗膀胱癌的分子标志物hsf1及其用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5652223A (en) * | 1994-03-14 | 1997-07-29 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | DNA encoding CAI resistance proteins and uses thereof |
CA2379264A1 (en) * | 1999-07-09 | 2001-01-18 | The Burnham Institute | A method for determining the prognosis of cancer patients by measuring levels of bag expression |
US20030073623A1 (en) * | 2001-07-30 | 2003-04-17 | Drmanac Radoje T. | Novel nucleic acid sequences obtained from various cDNA libraries |
ATE443259T1 (de) * | 2001-09-20 | 2009-10-15 | Univ Texas | Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests |
EP1323733A1 (en) * | 2001-12-28 | 2003-07-02 | Arturo Leone | BAG3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases |
US20090047689A1 (en) * | 2007-06-20 | 2009-02-19 | John Kolman | Autoantigen biomarkers for early diagnosis of lung adenocarcinoma |
WO2011044927A1 (en) * | 2009-10-12 | 2011-04-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A method for the diagnosis or prognosis of an advanced heart failure |
IT1397083B1 (it) * | 2009-12-04 | 2012-12-28 | Biouniversa Srl | Marcatore biochimico serico |
GB201017520D0 (en) * | 2010-10-15 | 2010-12-01 | Sense Proteomic Ltd | Biomarkers |
-
2012
- 2012-06-19 EP EP12172531.1A patent/EP2676966A1/en not_active Withdrawn
-
2013
- 2013-06-11 CN CN201380032196.6A patent/CN104619861A/zh active Pending
- 2013-06-11 KR KR20157001228A patent/KR20150036102A/ko not_active Application Discontinuation
- 2013-06-11 AU AU2013279604A patent/AU2013279604B2/en not_active Ceased
- 2013-06-11 BR BR112014031958A patent/BR112014031958A2/pt not_active IP Right Cessation
- 2013-06-11 KR KR1020157001313A patent/KR102150903B1/ko active IP Right Grant
- 2013-06-11 WO PCT/EP2013/061971 patent/WO2013189775A1/en active Application Filing
- 2013-06-11 CN CN201380032138.3A patent/CN104507965B/zh not_active Expired - Fee Related
- 2013-06-11 WO PCT/EP2013/061976 patent/WO2013189778A1/en active Application Filing
- 2013-06-11 AU AU2013279601A patent/AU2013279601A1/en not_active Abandoned
- 2013-06-11 JP JP2015517669A patent/JP2015521475A/ja active Pending
- 2013-06-11 EP EP13728375.0A patent/EP2861754A1/en not_active Ceased
- 2013-06-11 EP EP13728180.4A patent/EP2861618B1/en active Active
- 2013-06-11 CA CA2876872A patent/CA2876872A1/en not_active Abandoned
- 2013-06-11 ES ES13728180T patent/ES2795981T3/es active Active
- 2013-06-11 BR BR112014031957A patent/BR112014031957A2/pt not_active IP Right Cessation
- 2013-06-11 CA CA2876922A patent/CA2876922C/en active Active
- 2013-06-11 JP JP2015517672A patent/JP6654432B2/ja not_active Expired - Fee Related
- 2013-06-11 PL PL13728180T patent/PL2861618T3/pl unknown
-
2014
- 2014-12-11 IN IN10562DEN2014 patent/IN2014DN10562A/en unknown
- 2014-12-11 IN IN10561DEN2014 patent/IN2014DN10561A/en unknown
- 2014-12-16 US US14/572,654 patent/US10359433B2/en active Active
- 2014-12-16 US US14/572,445 patent/US20150132764A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2015529633A5 (ja) | ||
Meijers et al. | Heart failure stimulates tumor growth by circulating factors | |
Wu | Release of cardiac troponin from healthy and damaged myocardium | |
Quilici et al. | Circulating endothelial cell count as a diagnostic marker for non–ST-elevation acute coronary syndromes | |
Berezin et al. | Pattern of circulating microparticles in chronic heart failure patients with metabolic syndrome: Relevance to neurohumoral and inflammatory activation | |
Shere et al. | Circulating blood biomarkers in essential hypertension: a literature review | |
Cardinale et al. | Role of biomarkers in cardioncology | |
EA201070738A1 (ru) | Композиции и способы детекции tiab | |
BRPI1007867B8 (pt) | anticorpo recombinante ou fragmento de ligação ao antígeno do mesmo, composição farmacêutica e kit compreendendo o referido anticorpo, métodos de detecção de antígeno de troponina i em uma amostra de teste e métodos in vitro de diagnóstico de síndrome coronariana aguda ou infarto do miocárdio em um paciente | |
EA201792497A1 (ru) | Антитела к gitr для диагностики злокачественной опухоли | |
WO2013068374A3 (en) | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment | |
WO2011161062A3 (en) | Lipidomic biomarkers for identification of high-risk coronary artery disease patients | |
WO2013068373A3 (en) | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment | |
JP2014144959A5 (ja) | ||
Gruden et al. | Serum heat shock protein 27 levels in patients with hepatocellular carcinoma | |
CA2509063A1 (en) | Scd40l and placental growth factor (plgf) as biochemical marker combinations in cardiovascular diseases | |
Iversen et al. | Pregnancy associated plasma protein-A (PAPP-A) is not a marker of the vulnerable atherosclerotic plaque | |
FI3356827T3 (fi) | GDF-15 diagnostisena markkerina immuunivasteen vapauttajilla annetun hoidon hoitovasteen ennustamiseksi | |
Chen et al. | Association of serum angiopoietin‑1, angiopoietin‑2 and angiopoietin‑2 to angiopoietin‑1 ratio with heart failure in patients with acute myocardial infarction | |
Nyström et al. | Type IV collagen as a tumour marker for colorectal liver metastases | |
Villacorta et al. | Prognostic value of plasma neutrophil gelatinase-associated lipocalin in patients with heart failure | |
Vasatova et al. | Current applications of cardiac troponin T for the diagnosis of myocardial damage | |
WO2014167969A1 (ja) | 大腸がんの検出方法 | |
Schmid et al. | ST2 predicts survival in patients undergoing transcatheter aortic valve implantation | |
RU2670052C1 (ru) | Антигенный полипептид для выявления в плазме крови иммунного маркера - аутоантитела к vegfr1 и его применение |